Proximagen buys Minster in UK tie-up
This article was originally published in Scrip
Executive Summary
Proximagen Neuroscience has agreed to acquire Minster Pharmaceuticals for £4.3 million in cash. The pairing of the two UK companies will form a drug developer for psychiatric disorders and central nervous system and neurological diseases.